Positioning Lab Services to Meet the Changing Needs of Healthcare, Physicians, Patients, and Payers: How Five Primary Trends Create Profitable Opportunities for Your Laboratory
Positioning Lab Services to Meet the Changing Needs of Healthcare, Physicians, Patients, and Payers: How Five Primary Trends Create Profitable Opportunities for Your Laboratory by Jane Hermansen, Curtiss McNair, Scott Wallask...WHO Expands TB Diagnostic Toolkit with Point-of-Care Tests, Tongue Swabs, and Sample Pooling
WHO introduces faster, more accessible TB testing strategies while CDC maintains a targeted, risk-based approach in the United States.
The World Health Organization (WHO) has issued new recommendations aimed at improving access to faster, more efficient tuberculosis (TB) diagnostics by introducing near point-of-care molecular testing, alternative sample collection methods, and pooled testing strategies, according to a news release.
For the first time, WHO is recommending a new class of near point-of-care nucleic acid amplification tests (NPOC-NAATs) that can be deployed in decentralized settings such as primary care clinics and community health centers. These systems are designed to deliver faster results at lower cost compared to traditional laboratory-based molecular platforms, potentially shifting more TB testing closer to the patient.
Clinical laboratory scientists should note that the WHO’s guidelines diverge noticeably from those of the Centers for Disease Control and Prevention (CDC).
The updated guidance also endorses tongue swabs as an alternative specimen type for TB detection, particularly for patients unable to produce sputum. In parallel, WHO recommends sputum pooling as a strategy to improve efficiency and reduce costs, allowing laboratories to increase throughput while conserving reagents in resource-constrained environments.

“These new WHO recommendations mark a major step forward in making TB testing faster and more accessible,” said Tereza Kasaeva, director of WHO’s Department for HIV, TB, Hepatitis & STIs. “WHO urges countries and partners to work together to roll out these guidelines to close persistent diagnostic gaps and ensure that everyone with TB can be diagnosed early and start life-saving treatment without delay.” (Photo credit: WHO)
The recommendations arrive as global diagnostic gaps persist despite international commitments to expand access to rapid molecular testing. Many patients still experience delays due to reliance on sputum samples, centralized laboratory infrastructure, and the high cost of testing platforms.
New WHO Recommendations Emphasize Access and Efficiency
WHO’s updated Module 3: Diagnosis guidelines, expected later this year, reflect a broader shift toward decentralization and scalability in TB diagnostics.
By enabling testing at peripheral healthcare levels, the new NPOC-NAAT systems could reduce turnaround times and expand access in underserved regions. Tongue swabs further simplify sample collection, while pooling strategies offer laboratories a practical way to stretch limited resources without sacrificing diagnostic reach.
Supporting materials, including an operational handbook and implementation toolkit, will guide laboratories and national TB programs through adoption, training, and workflow integration.
CDC Maintains Targeted Testing Approach in the US
In contrast to WHO’s global push for expanded access, the CDC continues to emphasize a targeted testing strategy for tuberculosis in the United States, focusing on high-risk individuals rather than universal screening.
TB case counts and rates have been increasing since 2021, the CDC noted in late 2025. The US saw a 7.9% increase in case count and a 6.9% increase in rate in 2024 as compared to a year earlier. In 2024, there were 10,388 TB cases in the US with a corresponding incidence rate of 3.1 per 100,000 population.
Two Types of TB Infection Tests
The CDC recognizes two primary methods to detect TB infection, though neither distinguishes between latent infection and active disease:
- TB blood tests: Preferred for most individuals, particularly those vaccinated with Bacille Calmette-Guérin (BCG). (BCG is primarily used to prevent severe childhood TB particularly in high-prevalence countries. BCG is generally not recommended in the US.)
- TB skin test: Still used in certain cases, especially for children under age five, and for baseline testing scenarios requiring a two-step approach.
Five Components of a Full Diagnostic Evaluation
If a patient tests positive or presents symptoms such as chronic cough, night sweats, or weight loss, the CDC recommends a comprehensive evaluation that includes:
- Medical history and risk assessment
- Physical examination
- Chest X-ray
- Bacteriologic testing using sputum samples (typically three), including:
- NAAT for rapid detection
- Sputum smear microscopy
- Culture
- Drug susceptibility testing to guide treatment decisions
Updated Guidance for Healthcare Personnel
Recent CDC guidance, developed with the National Tuberculosis Controllers Association, reflects a shift in screening practices for healthcare workers:
- Baseline TB testing is required upon hire
- Routine annual testing is no longer recommended for most healthcare workers
- Post-exposure testing is advised immediately and again eight to 10 weeks later if initial results are negative
For 2026, the CDC emphasizes several important nuances for clinicians and laboratories interpreting TB test results. Blood-based interferon-gamma release assays (IGRAs) are strongly preferred for individuals who have received the BCG vaccine, as they are less likely to produce false-positive results compared to skin tests. In addition, for individuals considered low risk for TB, a positive result should be confirmed with a second test—ideally using a different method—before treatment is initiated, helping to avoid unnecessary therapy and ensure diagnostic accuracy.
Implications for Clinical Laboratories
Together, WHO and CDC guidance illustrate a divergence in strategy shaped by global versus domestic needs. WHO’s recommendations prioritize expanded access, decentralization, and cost efficiency—particularly in high-burden or resource-limited settings—while CDC guidance reflects a more targeted, risk-based approach within a lower-incidence environment.
For clinical laboratories, the evolving landscape signals both opportunity and complexity: Adoption of decentralized molecular platforms, validation of alternative specimen types, and optimization of high-throughput workflows such as pooling may become increasingly important as TB diagnostic strategies continue to evolve.
This article was created with the assistance of Generative AI and has undergone editorial review before publishing.
—Janette Wider
Ex-NFL Player Convicted in $328M Genetic Testing Fraud as Medicare Scrutiny Intensifies
Keith J. Gray’s conviction underscores rising enforcement and audit risk as Medicare spending shifts toward high-cost genetic testing.
A federal jury in Dallas has convicted Texas laboratory owner and former NFL player Keith J. Gray for orchestrating a $328 million Medicare fraud scheme tied to unnecessary cardiovascular genetic testing. Gray, age 39, owned and operated Axis Professional Labs LLC and Kingdom Health Laboratory LLC, which billed Medicare for tests that were not medically necessary, according to the US Department of Justice (DOJ).
The jury convicted Gray on multiple counts, including conspiracy to defraud the United States, violations of the Anti-Kickback Statute, and money laundering. He now faces up to 10 years in prison for each count, with sentencing to be determined by a federal judge.
Gray briefly pursued a professional football career after playing at the University of Connecticut, signing as an undrafted free agent with the Carolina Panthers in 2009 and later spending time on the Indianapolis Colts practice squad, though he never appeared in a regular-season NFL game, according to Fox Sports.
Kickbacks and Sham Contracts Drove Genetic Testing Fraud
According to evidence presented at trial, Gray paid illegal kickbacks to marketers in exchange for Medicare beneficiaries’ DNA samples, personal information, and signed physician orders, the DOJ said. These marketers relied on aggressive telemarketing tactics and a practice known as “doctor chasing,” in which they identified patients’ primary care physicians and pressured them to approve genetic testing orders, prosecutors noted. In many cases, these approvals were based on pre-screening conducted by non-medical personnel rather than legitimate clinical evaluations.
To conceal the scheme, Gray used sham contracts and falsified invoices that were labeled as payments for marketing services, software, or loans. In reality, these payments were structured to match per-sample kickbacks. “Evidence at trial included text messages between Gray and his co-conspirator becoming giddy over the amount of money they were making from Medicare,” the DOJ noted.

Photo credit: NFL Photos
The two laboratories billed Medicare approximately $328 million in fraudulent claims, resulting in about $54 million in payments. Gray used some of these proceeds to purchase luxury vehicles, including high-end trucks and SUVs, as part of efforts to launder the illicit funds.
The case was investigated by multiple federal and state agencies, including the FBI, HHS Office of Inspector General, Texas Medicaid Fraud Control Unit, and the VA Office of Inspector General, underscoring ongoing enforcement efforts targeting fraud in clinical laboratory testing.
The Gray case underscores exactly the risk highlighted in a recent article from The Dark Report on a report from the Department of Health and Human Services’ Office of Inspector General that found genetic tests make up just 5% of volume but now drive 43% of Medicare Part B lab spending. As Medicare spending becomes increasingly concentrated in high-cost genetic testing, enforcement agencies are intensifying scrutiny around medical necessity and billing practices.
Gray’s $328 million fraud scheme—built on kickbacks, questionable ordering practices, and medically unnecessary tests—reflects the same misbehaviors regulators are now targeting. Because of fraud cases such as this, honest laboratories must make greater effort to strengthen compliance, validate ordering patterns, and prepare for heightened audits in the molecular diagnostics space.
Strategies to mitigate diagnostic testing fraud will be a key focus at the 31st Annual Executive War College taking place in New Orleans April 28-29.
—Janette Wider
Digital Pathology Trends Show Slow Adoption in US but Also Movement to Connect to Patient Care More Directly
Danaher’s chief medical officer, Maximilian Schmid, says ‘infrastructure is there’ to push forward whole slide imaging.
Based on discussions at the recent Association for Diagnostics & Laboratory Medicine’s (ADLM) 2025 conference and observations from other sources, digital pathology trends continue to show sluggish adoption by clinical laboratories and anatomic pathology practices in the US. However, proponents of whole slide imaging say now is a prime opportunity to integrate the technology with a patient-centric care approach.
At least 65 vendors at the ADLM 2025 exhibitor hall indicated that their products touched whole slide imaging or digital pathology, showing this area is a hot focus for sellers.
Based on its customers, Leica has one of the largest installation bases of digital pathology scanners in the world. From that perspective, the technology is available, yet obstacles remain.
“The infrastructure is there,” said Maximilian Schmid, MD, chief medical officer at Danaher Diagnostics. “How do we bring it to the patients?”
Danaher Corporation, which held a press briefing at ADLM 2025, is parent company to Leica.

ADLM 2025 took place in Chicago July 27-31at McCormick Place. (Photo credit: Scott Wallask.)
Labcorp Report Notes Costs as a Barrier
Anyone who has followed the slow progression of digital pathology knows adoption from the diagnostic lab industry has been lukewarm. In 2024, Labcorp released a report about clinical laboratory trends that indicated cost remained a hurdle to further use of digital pathology scanners and software. Based on a survey of 115 US-based pathologists, lab managers, and lab directors, the report concluded that just 33% of respondents had started orplanned to implementdigital pathologyin lab workflows.
“Industry adoption of digital pathology has been slower than expected, largely due to high initial costs,” Deborah Sesok-Pizzini, MD, MBA, chief medical officer at Labcorp, told Today’s Clinical Lab at the time. That publication is a partner brand to Dark Daily.
Digital Pathology Trends are Rosier in Europe
Leica has been able to convey a message to its customers that despite the initial costs, the return on investment for digital pathology is high in terms of more accurate diagnoses and quicker processes, Schmid said.
“When I look ahead 10 years, digital pathology will be as normal to labs as H&E staining,” he predicted, referring to common hematoxylin and eosin stains.
He added that while Labcorp’s study reflected US trends, digital pathology adoption is stronger elsewhere, based on what Danaher and Leica see with customers.
“Europe seems to be a little bit ahead in terms digitization,” including with whole-slide imaging, he noted. However, even in the US, “academic medical centers are moving very fast in this direction.”
Schmid’s assertion about Europe is supported by other sources. For example, a business case published in July 2024 by the UK’s National Health Service (NHS) for Wales indicated that Northern Ireland and Scotland had near-fully digitized cellular pathology programs for the NHS, and England was building up its network. Wales was seen as trailing behind these countries.
“The national move towards scanning of histological material for primary diagnosis and more recently, the adoption of artificial intelligence (AI)/computational pathology to improve the accuracy, reliability and quality of reports, means that most pathologists, especially new trainees who are already using digital technology, will, in the future, choose to work in departments where digital technology will enhance and underpin their diagnosis thus benefiting the quality of patient care,” the NHS Wales business case paper stated.
Computational Pathology’s Growing Role
Computational pathology—in other words, the use of data science, information, and digital technologies for laboratory medicine—is a key to moving precision medicine forward via digital pathology, said Nicole Selenko-Gebauer, MD, MBA, group vice president and chief innovation officer at Danaher Diagnostics.
“We need to complement technology-driven focuses” with a patient-centric approach, Selenko-Gebauer added.
Even in 2022, The Dark Report had alerted its readers to the promise of computational pathology, noting Mayo Clinic Laboratories’ early success in launching related clinical assessment goals based on digital pathology and artificial intelligence. (If you’re not a Dark Report subscriber, check out our 14-day free trial.)
Taken at that viewpoint, digital pathology trends related to patient care will be an important milestone for the technology.
“A pivotal moment will be the clinical utilization of digital pathology—that it works and is accurate,” Schmid said.
—Scott Wallask


